Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy.

ABSTRACT: Immunoglobulin G (IgG) therapy is an established long-term treatment in chronic inflammatory demyelinating polyneuropathy (CIDP) that is commonly administered intravenously (IVIg). The subcutaneous immunoglobulin (SCIg) administration route is a safe and effective alternative option, approved by the United States Food and Drug Administration (FDA) in 2018, for maintenance treatment of adults with CIDP. Physicians and patients alike need to be aware of all their treatment options in order to make informed decisions and plan long-term treatment strategies. In this review, we collate the evidence for SCIg in CIDP from all published studies and discuss their implications and translation to clinical practice. We also provide guidance on the practicalities of how and when to transition patients

SUBMITTER: Goyal NA 

PROVIDER: S-EPMC8457117 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature